Education
About Us
Working with TipRanks
Follow Us
Vaxcyte, Inc. (PCVX)
NASDAQ:PCVX
Total Valuation
Vaxcyte has a market cap or net worth of $5.72B. The enterprise value is $3.28B.
Market Cap$5.72B
Enterprise Value$3.28B
Share Statistics
Vaxcyte has 130,906,270 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding130,906,270
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Vaxcyte’s return on equity (ROE) is -0.14 and return on invested capital (ROIC) is -16.87%.
Return on Equity (ROE)-0.14
Return on Assets (ROA)-0.13
Return on Invested Capital (ROIC)-16.87%
Return on Capital Employed (ROCE)-0.17
Revenue Per Employee0.00
Profits Per Employee-1.12M
Employee Count414
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Vaxcyte is ―. Vaxcyte’s PEG ratio is 2.62.
PE Ratio―
PS Ratio0.00
PB Ratio3.02
Price to Fair Value3.02
Price to FCF-21.02
Price to Operating Cash Flow-12.14
PEG Ratio2.62
Income Statement
In the last 12 months, Vaxcyte had revenue of 0.00 and earned -463.93M in profits. Earnings per share was -3.80.
Revenue0.00
Gross Profit0.00
Operating Income-569.55M
Pretax Income-463.93M
Net Income-463.93M
EBITDA-448.08M
Earnings Per Share (EPS)-3.80
Cash Flow
In the last 12 months, operating cash flow was -542.15M and capital expenditures -49.31M, giving a free cash flow of -591.45M billion.
Operating Cash Flow-542.15M
Free Cash Flow-591.45M
Free Cash Flow per Share-4.52
Dividends & Yields
Vaxcyte pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.62
52-Week Price Change-50.05%
50-Day Moving Average44.80
200-Day Moving Average39.72
Relative Strength Index (RSI)41.88
Average Volume (3m)1.44M
Important Dates
Vaxcyte upcoming earnings date is Mar 2, 2026, After Close (Confirmed).
Last Earnings DateNov 4, 2025
Next Earnings DateMar 2, 2026
Ex-Dividend Date―
Financial Position
Vaxcyte as a current ratio of 12.75, with Debt / Equity ratio of 2.92%
Current Ratio12.75
Quick Ratio12.75
Debt to Market Cap0.00
Net Debt to EBITDA0.71
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Vaxcyte has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Vaxcyte EV to EBITDA ratio is -21.58, with an EV/FCF ratio of -20.36.
EV to Sales0.00
EV to EBITDA-21.58
EV to Free Cash Flow-20.36
EV to Operating Cash Flow-21.36
Balance Sheet
Vaxcyte has $1.71B in cash and marketable securities with $84.44M in debt, giving a net cash position of $1.63B billion.
Cash & Marketable Securities$1.71B
Total Debt$84.44M
Net Cash$1.63B
Net Cash Per Share$12.43
Tangible Book Value Per Share$27.10
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Vaxcyte is $100.80, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$100.80
Price Target Upside134.09% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast-5.21%